Clinical Trial Detail

NCT ID NCT04081389
Title Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Celecoxib + Cyclophosphamide + Doxorubicin + Interferon alpha-2b + Paclitaxel + Rintatolimod

Age Groups: adult senior

No variant requirements are available.